Summary of HRES 172: Raising awareness for the sarcoma cancer chordoma

Overview

• Bill Number: HRES 172
• Title: Raising awareness for the sarcoma cancer chordoma
• Type: House Resolution (non-binding)
• Purpose: Expresses the sense of the House that chordoma patients and families need increased funding and support in key areas related to diagnosis, treatment development, research-to-treatment transitions, and patient-centered drug discovery.
• Status: Referred to the House Committee on Energy and Commerce
• Introduced: February 27, 2025

What the bill does

• This is a non-binding resolution that does not create new law or authorize new spending. Instead, it signals the sense of the House regarding priorities for chordoma-related issues and directs attention to specific needs.

Key provisions (as introduced)

The resolution states that chordoma patients and families need increased funding and support for four areas:
1. Accurate and early diagnosis

2. Development of new treatments, diagnostics, and cures

3. Fewer hurdles between research and new treatments

4. Patient-centric approaches to drug discovery and development

Sponsors

• Primary sponsor: Rep. Henry C. "Hank" Johnson
• Cosponsors: Rep. Eleanor Holmes Norton, Rep. Lucy McBath, Rep. Nydia M. Velázquez, Rep. Frederica S. Wilson

Who is affected

• Chordoma patients and families: Primary beneficiaries through heightened attention to diagnosis, treatment options, and research efforts.
• Researchers and medical developers: Encouraged focus on faster translation from research to treatments and on patient-centered drug discovery.
• Federal entities (informational/advocacy impact): Agencies like the NIH/NCI and other researchers and stakeholders may be encouraged to pursue chordoma-focused initiatives in line with the resolution’s sense of priority; no specific mandates or funding authorizations are included in the text provided.

Procedural and timeline notes

• Introduced on February 27, 2025.
• Referred to the House Committee on Energy and Commerce for consideration. No further actions are listed in the provided information.

Potential impact and context

• As a non-binding resolution, HRES 172 primarily serves to raise awareness and articulate congressional priorities.
• It could influence future legislative or appropriations discussions by highlighting chordoma as a area needing attention and by signaling support for related initiatives in diagnosis, research, and patient-centered care.
• The resolution could help mobilize patients, clinicians, researchers, and advocacy groups to advocate for funding and programmatic efforts aligned with the four areas identified.